Roche Agrees to Acquire U.S.-Based PathAI
Swiss pharmaceutical giant Roche agreed to acquire U.S.-based PathAI for $750 million upfront plus up to $300 million in milestone payments. The deal aims to strengthen Roche's position in AI-driven d
reuters · 2026-05-06 22:51